Company intelligence / Profile preview

Plexaa

London, England, United Kingdomdigitalhealth.london ↗

Ownership: Private
Development stage: Preclinical

Overview

Plexaa’s BLOOM43 platform is a wearable medical device designed to reduce wound healing complications in breast cancer surgery and reconstruction by using controlled heat-based preconditioning. Proof-of-concept clinical trials have shown reduced rates of skin necrosis and re-operation. The product has won the MedTech World Femtech Product of the Year award and is currently being trialed at Stanford University Hospital with plans for commercial launch in 2025[1][2][3].

Therapeutic areas: OncologyWomen's Health
Modalities: DeviceNon-pharmacological therapy (wearable medical device for preconditioning)
Industry: Therapeutic Medical Devices

Partnerships

Panasonic Manufacturing UK (contract manufacturing partner)[1][4]

Beyond the preview

Go deeper on Plexaa.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Plexaa.

Explore the full profile